Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators.
暂无分享,去创建一个
E. Antman | R. Giugliano | K. Anderson | E. Braunwald | F. Van de Werf | C. McCabe | E. Braunwald | I. Menown | N. Kleiman | C. Gibson | A. Vahanian | H. Rupprecht | A. Adgey | A. Adgey | C. McCabe | R. van der Wieken | J. Ducas | R. Giugliano | P. Coussement | J. Scherer | C. Mccabe | C. Gibson | C. Mccabe
[1] J. López-Sendón,et al. Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction: a double-blind, randomized angiographic trial of lanoteplase versus alteplase. , 1998, Circulation.
[2] J. Burchenal,et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. , 1998, Circulation.
[3] C. Davies,et al. Failed coronary thrombolysis , 1998, The Lancet.
[4] E. Ohman,et al. Survival benefit of Abciximab administration during early rescue angioplasty: analysis of 387 patients from the GUSTO-III trial , 1998 .
[5] M. Simoons,et al. Combined Therapy With Streptokinase and Integrilin , 1998 .
[6] C. Wilson,et al. Low molecular weight heparin versus unfractionated heparin following thrombolysis in myocardial infarction , 1998 .
[7] J. Burchenal,et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. , 1998, Circulation.
[8] J. Muhlestein,et al. "Rescue" utilization of abciximab for the dissolution of coronary thrombus developing as a complication of coronary angioplasty. , 1997, Journal of the American College of Cardiology.
[9] B. Coller. GPIIb/IIIa Antagonists: Pathophysiologic and Therapeutic Insights from Studies of c7E3 Fab , 1997, Thrombosis and Haemostasis.
[10] M. Simoons,et al. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. , 1997, The New England journal of medicine.
[11] I. Palacios,et al. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Observations in animals and humans. , 1997, Circulation.
[12] T. Investigators,et al. A comparison of reteplase with alteplase for acute myocardial infarction , 1997 .
[13] E. Braunwald,et al. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. , 1997, Circulation.
[14] E. Antman. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. , 1996, Circulation.
[15] R. Califf,et al. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators. , 1996, The American journal of cardiology.
[16] E. Braunwald,et al. TIMI frame count: a quantitative method of assessing coronary artery flow. , 1996, Circulation.
[17] Coller Bs. Augmentation of thrombolysis with antiplatelet drugs. , 1995 .
[18] E. Braunwald,et al. Prognostic significance of nonfatal reinfarction during 3-year follow-up: results of the Thrombolysis in Myocardial Infarction (TIMI) phase II clinical trial. The TIMI Investigators. , 1995, Journal of the American College of Cardiology.
[19] L. Brass. Issues in the Development of Thrombin Receptor Antagonists , 1995, Thrombosis and Haemostasis.
[20] M. Carr,et al. Glycoprotein IIb/IIIa Blockade Inhibits Platelet-mediated Force Development and Reduces Gel Elastic Modulus , 1995, Thrombosis and Haemostasis.
[21] D. Ardissino,et al. Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction. , 1995, Journal of the American College of Cardiology.
[22] B. Coller. Augmentation of thrombolysis with antiplatelet drugs. , 1995, Coronary artery disease.
[23] C. Cannon,et al. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. , 1994, Journal of the American College of Cardiology.
[24] C. Cannon,et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. , 1994, Journal of the American College of Cardiology.
[25] D. Devine,et al. Factor XIIIa binding to activated platelets is mediated through activation of glycoprotein IIb-IIIa. , 1994, Blood.
[26] Walker,et al. Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .
[27] H. Weisman,et al. A chimeric murine/human antibody Fab fragment directed against the platelet GPIIb/IIIa receptor enhances and sustains arterial thrombolysis with recombinant tissue-type plasminogen activator in baboons. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.
[28] Gusto Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. , 1993, The New England journal of medicine.
[29] R. Califf,et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. , 1993, Journal of the American College of Cardiology.
[30] Frans Van de Werf,et al. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.
[31] B. Coller. Inhibitors of the platelet glycoprotein IIb/IIIa receptor as conjunctive therapy for coronary artery thromboiysis , 1992 .
[32] H. Hellstrom. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. , 1991, Circulation.
[33] H. Gold,et al. Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody. , 1990, Journal of the American College of Cardiology.
[34] R. Califf,et al. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group. , 1990, Circulation.
[35] B. Coller. Platelets and thrombolytic therapy. , 1990, The New England journal of medicine.
[36] U. Tebbe,et al. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. , 1989, Journal of the American College of Cardiology.
[37] J. May,et al. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis. , 1989, Circulation.
[38] L. Bolognese,et al. RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2 , 1988, The Lancet.
[39] K. Friedman,et al. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. , 1988, Blood.
[40] Dwight E. Peake,et al. Thrombolysis in myocardial infarction (TIMI) trial: Phase I. A comparison between intravenous tissue plasminogen activator and intravenous streptokinase , 1988 .
[41] H. Gold,et al. Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. , 1988, The Journal of clinical investigation.
[42] G. FitzGerald,et al. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. , 1988, Circulation.
[43] R Roberts,et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. , 1987, Circulation.
[44] Harold T. Dodge,et al. Thrombolysis inMyocardial Infarction (TIMI) Trial, Phase I:acomparison between intravenous tissue plasminogen activator andintravenous streptokinase* , 1987 .
[45] Richard J. Jones. Heart Disease: A Textbook of Cardiovascular Medicine , 1980 .
[46] E. Braunwald. Heart Disease: A Textbook of Cardiovascular Medicine , 1992, Annals of Internal Medicine.
[47] E. Veys,et al. HL-A AND INFECTIVE SACROILEITIS , 1974 .
[48] J. Andel. Sequential Analysis , 2022, The SAGE Encyclopedia of Research Design.